Question 1

What is Eli Lilly's P/S ratio?

Accepted Answer

Eli Lilly (LLY) P/S ratio is 14.4× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Eli Lilly?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Eli Lilly specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Eli Lilly's P/S ratio high or low?

Accepted Answer

Eli Lilly's P/S ratio of 14.4× is above its own 5-year average of 13.3× and above the sector median of 3.4×. That places the current reading at the 52th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Eli Lilly's historical P/S ratio range?

Accepted Answer

In the available daily series, Eli Lilly (LLY) P/S ratio has ranged from a low of 1.6× in 2010 to a high of 23.9× in 2024. The 5-year average is 13.3× and the 5-year median is 12.7×.

Question 7

What was Eli Lilly's P/S ratio in 2025?

Accepted Answer

Eli Lilly (LLY) P/S ratio at the end of 2025 was 14.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Eli Lilly's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$965B	$65.2B	14.8×	-0.6×	Dec 31, 2025
2024	$693B	$45B	15.4×	+0.0×	Dec 31, 2024
2023	$524B	$34.1B	15.4×	+3.2×	Dec 31, 2023
2022	$348B	$28.5B	12.2×	+2.9×	Dec 31, 2022
2021	$263B	$28.3B	9.3×	+2.7×	Dec 31, 2021
2020	$162B	$24.5B	6.6×	+0.9×	Dec 31, 2020
2019	$126B	$22.3B	5.6×	+0.3×	Dec 31, 2019
2018	$119B	$22.3B	5.3×	+1.4×	Dec 31, 2018
2017	$88.9B	$22.9B	3.9×	+0.1×	Dec 31, 2017
2016	$81B	$21.2B	3.8×	-0.9×	Dec 31, 2016
2015	$93.1B	$20B	4.7×	+0.8×	Dec 31, 2015
2014	$76.6B	$19.6B	3.9×	+1.4×	Dec 31, 2014
2013	$57B	$23.1B	2.5×	-0.0×	Dec 31, 2013
2012	$56.5B	$22.6B	2.5×	+0.6×	Dec 31, 2012
2011	$46.4B	$24.3B	1.9×	+0.2×	Dec 31, 2011
2010	$38.9B	$23.1B	1.7×	-0.1×	Dec 31, 2010
2009	$39.2B	$21.8B	1.8×	-0.4×	Dec 31, 2009
2008	$44.1B	$20.4B	2.2×	-1.0×	Dec 31, 2008
2007	$58.2B	$18.6B	3.1×	-0.5×	Dec 31, 2007
2006	$56.5B	$15.7B	3.6×	-0.6×	Dec 31, 2006
2005	$61.5B	$14.6B	4.2×	-0.2×	Dec 31, 2005
2004	$61.4B	$13.9B	4.4×	-1.6×	Dec 31, 2004
2003	$75.9B	$12.6B	6.0×	-0.1×	Dec 31, 2003
2002	$68.3B	$11.1B	6.2×	—	Dec 31, 2002


Zimmer Biomet Holdings (ZBH)	2.1×
AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
UnitedHealth Group (UNH)	0.8×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
Elevance Health (ELV)	0.4×
Teladoc Health (TDOC)	0.4×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Eli Lilly (LLY) 2002-2026

P/S Ratio daily chart for Eli Lilly (LLY)

Historical P/S Ratio for Eli Lilly (LLY) from 2002 to 2025

About P/S Ratio at Eli Lilly (LLY)

Eli Lilly P/S Ratio by Year

Eli Lilly P/S Ratio 2025: 14.8×

Eli Lilly P/S Ratio 2024: 15.4×

Eli Lilly P/S Ratio 2023: 15.4×

Eli Lilly P/S Ratio 2022: 12.2×

Eli Lilly P/S Ratio 2021: 9.3×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Eli Lilly (LLY) Key Financials